Overview of Dr. Ritchie
Dr. Ellen Ritchie is a malignant hematologist in New York, NY and is affiliated with Weill Cornell Medicine-New York Presbyterian Hospital in NYC. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 20 years. She specializes in hematologic oncology and is experienced in leukemia, MDS, MPNs. She has more than 100 publications and over 500 citings.
Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021- Is this information wrong?
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2000 - 2004
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1997
Certifications & Licensure
- NY State Medical License 1999 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
- Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Start of enrollment: 2013 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 75 citationsCPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie
The Lancet. Haematology. 2021-07-01 - 573 citationsCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19 - 363 citationsSomatic mutations precede acute myeloid leukemia years before diagnosis.Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang
Nature Medicine. 2018-07-01
Journal Articles
- Somatic Mutations Precede Acute Myeloid Leukemia Years Before DiagnosisSangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature
Abstracts/Posters
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- CPX-351 As First Intensive Therapy for Elderly Patients with AML61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Authored Content
- Clinical Trial Patient Shortage Will Hinder the Progress of AML Drug DevelopmentDecember 2018
Press Mentions
- Nobody Wants Cancer. But a ‘Big C’ Label Has Surprising UpsidesMarch 11th, 2021
- Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 2nd, 2019
- Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness MonthSeptember 1st, 2017
- Join now to see all
Professional Memberships
- Member
- Member
Hospital Affiliations
- New York-Presbyterian HospitalNew York, New York
- New York-Presbyterian HospitalNew York, New York
- New York-Presbyterian HospitalNew York, New York
- NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Missouri - HMO/POS
Empire BCBS HMO
Empire BCBS PPO
GHI PPOGreat West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: